PERISYL COMBI 4/1.25  perindopril erbumine/indapamide hemihydrate 4mg/1.25mg tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

perisyl combi 4/1.25 perindopril erbumine/indapamide hemihydrate 4mg/1.25mg tablet blister pack

alphapharm pty ltd - perindopril erbumine, quantity: 4 mg; indapamide hemihydrate, quantity: 1.25 mg - tablet - excipient ingredients: sodium bicarbonate; microcrystalline cellulose; lactose; colloidal anhydrous silica; magnesium stearate - treatment of hypertension. treatment should not be initiated with this combination

OLMERTAN COMBI 20/12.5 olmesartan medoxomil and hydrochlorothiazide 20/12.5 mg tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

olmertan combi 20/12.5 olmesartan medoxomil and hydrochlorothiazide 20/12.5 mg tablet blister pack

pharmacor pty ltd - olmesartan medoxomil, quantity: 20 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet - excipient ingredients: lactose monohydrate; hyprolose; purified water; magnesium stearate; microcrystalline cellulose; stearic acid; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

OLMERTAN COMBI 40/25 olmesartan medoxomil and hydrochlorothiazide 40/25 mg tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

olmertan combi 40/25 olmesartan medoxomil and hydrochlorothiazide 40/25 mg tablet blister pack

pharmacor pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg - tablet - excipient ingredients: magnesium stearate; stearic acid; hyprolose; lactose monohydrate; microcrystalline cellulose; purified water; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

OLMERTAN COMBI 40/12.5 olmesartan medoxomil and hydrochlorothiazide 40/12.5 mg tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

olmertan combi 40/12.5 olmesartan medoxomil and hydrochlorothiazide 40/12.5 mg tablet blister pack

pharmacor pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet - excipient ingredients: hyprolose; microcrystalline cellulose; stearic acid; purified water; lactose monohydrate; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red; macrogol 400 - olmesartan medoxomil and hydrochlorothiazide is indicated for:,treatment of hypertension.,treatment should not be initiated with this fixed dose combination.

RECOMBIVAX HB SUSPENSION Kanada - Englisch - Health Canada

recombivax hb suspension

merck canada inc - hepatitis b surface antigen (recombinant) - suspension - 10mcg - hepatitis b surface antigen (recombinant) 10mcg - vaccines

RECOMBIVAX HB SUSPENSION Kanada - Englisch - Health Canada

recombivax hb suspension

merck canada inc - hepatitis b surface antigen (recombinant) - suspension - 40mcg - hepatitis b surface antigen (recombinant) 40mcg - vaccines

PREZCOBIX darunavir/cobicistat 800 mg/150 mg film coated tablet bottle Australien - Englisch - Department of Health (Therapeutic Goods Administration)

prezcobix darunavir/cobicistat 800 mg/150 mg film coated tablet bottle

janssen-cilag pty ltd - darunavir, quantity: 800 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; silicon dioxide; magnesium stearate; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - prezcobix, a fixed dose combination of darunavir and cobicistat, is indicated in combination with other antiretroviral agents for the treatment of adult patients with human immunodeficiency virus- 1 (hiv-1) infection in:,- antiretroviral treatment-naive patients,- antiretroviral treatment-experienced patients with no darunavir resistance associated mutations and who have plasma hiv-1 rna <100,000 copies/ml,- antiretroviral treatment-experienced but hiv protease inhibitor-naive patients for whom hiv-1 genotype testing is unavailable (see section 4.2 dose and method of administration)